PCVX Vaxcyte, Inc.
Price Chart
Executive Summary
Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Group A Streptococcus. This is an early-stage clinical milestone with no efficacy data yet; topline results are not expected until H2 2027.
Actionable Insight
This is a routine early-stage clinical update with no data readout until H2 2027. No immediate catalyst for the stock. Monitor for DSMB safety reviews and any interim updates, but the next material event is topline data release.
Key Facts
- First participant dosed in Phase 1 study of VAX-A1 for Group A Strep.
- Study is randomized, double-blind, placebo-controlled, dose-escalation, two-stage, enrolling ~80 healthy adults aged 18-40.
- Primary objective: safety and tolerability; secondary: antigen-specific immune responses.
- Topline data expected in second half of 2027.
- Group A Strep causes ~800M new cases and >600,000 deaths annually worldwide; no approved vaccine exists.
- VAX-A1 targets four conserved antigens (ScpA, SLO, SpyAD, modified GACPR) using Vaxcyte's cell-free protein synthesis platform.
Financial Impact
No financial data disclosed; early-stage clinical milestone with no revenue impact.
Risk Factors
- Clinical failure or safety issues in Phase 1 could halt the program.
- Long timeline to data (H2 2027) means no near-term catalyst.
- Group A Strep vaccine development has historically been challenging with prior failures.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305592 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
Press Release
| $46.93 $48.76 | ▲ +3.90% | ▲ +3.49% | $47.36 (+0.92%) |
|
May 6, 2026
4w ago
|
8-K
| $51.48 $53.01 | ▼ −2.97% | ▼ −2.14% | $47.36 (+8.00%) |
|
Apr 23, 2026
6w ago
|
DEFA14A
| $59.49 $59.72 | ▲ +0.39% | ▲ +0.22% | $47.36 (−20.39%) |
|
Apr 1, 2026
9w ago
|
Insider Cluster
| $58.50 $58.38 | ▼ −0.21% | ▼ −0.28% | $47.36 (−19.04%) |
|
Mar 23, 2026
10w ago
|
Press Release
| $55.94 $54.67 | ▼ −2.27% | ▼ −1.91% | $47.36 (−15.34%) |
|
Feb 24, 2026
14w ago
|
8-K
| $63.04 $60.00 | ▼ −4.82% | ▼ −4.28% | $47.36 (−24.87%) |
|
Feb 24, 2026
14w ago
|
8-K
| $63.04 $60.00 | ▼ −4.82% | ▼ −4.28% | $47.36 (−24.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access